Life Sciences

Oligo Factory, a Holliston biomanufacturer, has become compliant with Good Manufacturing Practices, nine months after the company added 13,000 square feet to increase its manufacturing capacity.

The state’s buzziest industry slowed down this year, although some sectors will do better than others next year.

The reverberations of the coronavirus pandemic’s impact will continue to impact the manufacturing space in 2024, as companies face challenges in adapting to supply chain shortages in certain sectors like pharmaceuticals, worker shortages, increased costs, and changing consumer trends.

Every December for this Economic Forecast special edition, the journalists in the WBJ newsroom forecast 10 possible news events for the coming year, based on their expertise and the trends in the Central Massachusetts business community.

Beacon MedTech Solutions in Leominster has named Jim Colony as president of the company. He was previously interim president, a position he took on in March.

Hopkinton’s Isto Biologics completed a merger with a California biologics company known for innovation in October.

Worcester incubator Massachusetts Biomedical Initiatives has entered a sponsorship with Thermo Fisher Scientific in Waltham, which will support an updated and state-of-the-art instrument suite at the Worcester startup hub.

UMass Chan Medical School is reducing its workforce at its Boston biologics and vaccine manufacturing division, MassBiologics, with more layoffs potentially coming in the next 90 days.

Alzheon, a Framingham-based biopharmaceutical company, has promoted Glenn Pauly to chief commercial officer and appointed two new vice presidents.

Chicago-based biotech giant AbbVie, which has a large bioresearch facility in Worcester, will acquire Waltham’s ImmunoGen and its flagship ovarian cancer treatment drug in an more than $10-billion transaction.